Diplomat Pharmacy, Inc. (DPLO) Receives Consensus Recommendation of “Hold” from Brokerages
Diplomat Pharmacy, Inc. (NYSE:DPLO) has been given a consensus rating of “Hold” by the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $17.89.
DPLO has been the subject of a number of research reports. Barclays PLC set a $20.00 target price on shares of Diplomat Pharmacy and gave the stock a “buy” rating in a report on Tuesday, May 9th. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Bank of America Corporation raised their target price on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the stock a “neutral” rating in a report on Thursday, May 25th. Mizuho raised their target price on shares of Diplomat Pharmacy from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, May 16th. Finally, Leerink Swann restated a “market perform” rating and set a $18.00 target price (up from $16.00) on shares of Diplomat Pharmacy in a report on Wednesday, May 17th.
Several large investors have recently modified their holdings of DPLO. BlackRock Inc. increased its stake in shares of Diplomat Pharmacy by 158,977.3% in the first quarter. BlackRock Inc. now owns 5,548,617 shares of the company’s stock valued at $88,501,000 after buying an additional 5,545,129 shares during the period. Frontier Capital Management Co. LLC purchased a new stake in shares of Diplomat Pharmacy during the first quarter valued at approximately $87,015,000. Redmile Group LLC increased its stake in shares of Diplomat Pharmacy by 718.1% in the first quarter. Redmile Group LLC now owns 1,254,342 shares of the company’s stock valued at $20,007,000 after buying an additional 1,101,025 shares during the period. Victory Capital Management Inc. increased its stake in shares of Diplomat Pharmacy by 52,972.3% in the first quarter. Victory Capital Management Inc. now owns 961,140 shares of the company’s stock valued at $15,330,000 after buying an additional 959,329 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Diplomat Pharmacy by 14.2% in the first quarter. Vanguard Group Inc. now owns 3,866,811 shares of the company’s stock valued at $61,676,000 after buying an additional 481,710 shares during the period. Institutional investors and hedge funds own 72.02% of the company’s stock.
Shares of Diplomat Pharmacy (DPLO) opened at 15.26 on Tuesday. The stock’s 50 day moving average is $16.05 and its 200-day moving average is $15.66. Diplomat Pharmacy has a 52-week low of $12.25 and a 52-week high of $38.94. The firm has a market capitalization of $1.02 billion, a P/E ratio of 60.80 and a beta of 0.66.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. The firm had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.14 billion. Diplomat Pharmacy had a net margin of 0.38% and a return on equity of 7.91%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.23 earnings per share. On average, equities analysts forecast that Diplomat Pharmacy will post $0.66 earnings per share for the current fiscal year.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.